twoXAR Announces Preclinical Proof-of-Concept Data on Novel Liver Cancer Candidate

07:40 EDT 14 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, today announced that its candidate targeting hepatocellular carcinoma (HCC or Liver Cancer), TXR-311, has shown positive results in cell-base...

Other Sources for this Article

for twoXAR
Colin Sanford, 415-946-1094


More From BioPortfolio on "twoXAR Announces Preclinical Proof-of-Concept Data on Novel Liver Cancer Candidate"

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...